Gross-to-Net Benchmark Survey Report 2022

In the pharmaceutical and biotech industry, the term Gross-to-Net (GTN) has developed into more than just the financial management and forecasting of manufacturer’s discounts. The GTN umbrella encompasses all aspects of revenue management, reporting, and analytics.

To add value to the industry, the Revenue Analytics Collaborative (RAC) began surveying its members seven years ago to document GTN successful practices and trends. Needless to say, a lot has changed in the life sciences industry since we began RAC surveys in 2015.

Download now!

Rg Paper
adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand paper article